SILO - Psyched: DMT & SSRIs For Depression MDMA Training Negative Responses To Psychedelics & More | Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
They correspond to U.K.’s short-acting psychedelic therapies developer Small Pharma’s (OTCMKTS: DMTTF) open-label Phase 1b study assessing the joint work of its "native” DMT compound, SPL026 and selective serotonin reuptake inhibitors (SSRIs.) Read more HERE.
Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program, Legal Medical Psilocybin Access For Veteran Approved
Canadian not-for-profit organization TheraPsil has received board approval to launch its training program on MDMA-assisted psychotherapy for trauma survivors. TheraPsil has been advancing legal access to psychedelic-assisted psychotherapy since 2019.
The new course, which joins the "Fundamentals of Psilocybin-Assisted Psychotherapy” programs that have already trained 500+ healthcare professionals, extends the nonprofit's advocacy efforts toward including both psilocybin and MDMA for patients in medical need through the country’s Special Access Program (SAP.) Find out more HERE.
Meanwhile, the SAP has authorized a physician to provide Apex Labs’ psilocybin macrodose drug protocol to patient Kelsi Sheren, a Canadian veteran, as therapy for her Treatment Resistant Depression (TRD) within PTSD starting October 2023.
APEX-90 consists of a psilocybin drug product paired with psychotherapy as per Apex’s SUMMIT-90 clinical trial protocol; specifically, following an Investigator Brochure (IB) and Therapy Manual (TM) pertaining to the protocol of the company’s Health Canada-approved 160-patient Phase 2b clinical trial. Continue reading HERE.
Analyzing Long-Term Negative Responses To Psychedelics: Researchers Release Study
The journal Nature published a new research analysis from Imperial College London (ICL)’s Center for Psychedelic Research and University of California ...